A5009801511- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Head and Neck Cancer Studies
- Ferroptosis and cancer prognosis
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Glycosylation and Glycoproteins Research
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Mycobacterium research and diagnosis
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Immune Cell Function and Interaction
- Cancer Cells and Metastasis
- RNA modifications and cancer
- Breast Cancer Treatment Studies
- Macrophage Migration Inhibitory Factor
- Cell Adhesion Molecules Research
- Cancer Research and Treatments
- Ovarian cancer diagnosis and treatment
- Biomarkers in Disease Mechanisms
- Colorectal and Anal Carcinomas
- Cancer and Skin Lesions
Yale New Haven Health System
2025
Yale University
2022-2024
IE University
2024
MVJ Medical College and Research Hospital
2017
Programmed cell death protein-1 (PD-1)-targeted immunotherapy is approved for recurrent or metastatic head and neck squamous carcinoma (R/M HNSCC) treatment. Although its efficacy correlates with PD-L1 expression, response limited even among positive cases. We employed digital spatial profiling (DSP) to discover potential biomarkers of outcomes in HNSCC. Fifty prospectively collected, pretreatment biopsy samples from patients anti-PD-1-treated R/M HNSCC, were assessed using DSP, 71 proteins...
Antibody-drug conjugates (ADCs) are a promising approach for the management of patients with non-small cell lung cancer (NSCLC). However, only small subset derive benefit from these therapies. We employed quantitative immunofluorescence (QIF) assays to measure levels four ADC target proteins (HER2, TROP2, HER3, EGFR) in three NSCLC tissue microarray cohorts stratified according EGFR mutation (EGFRmut (n=83), EGFRwt (n=128), and unknown (n=232)). Assay limits were established by mass...
Abstract We assessed the predictive value of an image analysis-based tumor-infiltrating lymphocytes (TILs) score for pathologic complete response (pCR) and event-free survival in breast cancer (BC). About 113 pretreatment samples were analyzed from patients with stage IIB-IIIC HER-2-negative BC randomized to neoadjuvant chemotherapy ± bevacizumab. TILs quantification was performed on full sections using QuPath open-source software a convolutional neural network cell classifier (CNN11). used...
Basal Cell Adhesion Molecule (BCAM), a receptor for laminin subunit α5, plays crucial role in the pathogenesis of various malignancies. Notably, evidence hypermethylation at multiple immune checkpoints patients with low BCAM expression suggests these individuals may respond favorably to immunotherapy using ICIs (immune checkpoint inhibitors). This finding lays foundation hypothesis that serve as an important biomarker cancer patients. To investigate this potential, we evaluated patterns 3114...
Targeting the interaction of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) and its ligands has been shown to reinstate antitumor immunity. In addition, introduction LAIR-1 decoy protein, LAIR-2, sensitizes previously resistant lung tumors programmed death-1 (PD-1) blockade, indicating potential as an alternative marker for anti-PD-1 resistance in cancer. Here, we assessed compared with death-ligand 1 (PD-L1) expression various tumors, a focus on non-small cell cancer (NSCLC)...
Abstract Sacituzumab govitecan (SG) is an antibody-drug conjugate that targets human trophoblast cell-surface antigen 2 (TROP2), which expressed in over 90% of breast cancer cases (Zaman et al, 2019). By delivering the cytotoxic SN-38 (topoisomerase I inhibitor) to TROP2 expressing cells, SG showed promising antitumor activities clinical trials and now approved treatment for triple-negative (TNBC) hormone receptor (HR)-positive HER2-negative metastatic setting. Despite prevalent expression...
6050 Background: Immunotherapy (ITx) has become the standard of care in treatment recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, response rate is limited to 13-18% patients, underlining need identify mechanisms implicated resistance. This study aims uncover novel biomarkers ITx outcomes R/M HNSCC using digital spatial profiling (DSP) technology. Methods: Pre-treatment biopsy samples 50 ITx-treated constructed form tissue microarray (YTMA496), were...
<p>LAIR-1 expression in different molecular subtypes of within Storma and Tumor. (A) Umap (Uniform Manifold Approximation Projection) plot showing the LAIR-1 RNA patient lung tumor biopsies (n=7) derived single cell RNA-seq data. (B) Quantification LM22 immune cells highest macrophages.</p>
<p>Target-protein panels included in the GeoMxTM Immuno-Oncology Human Protein Assay</p>
<p>clinical characteristics of discovery (Athens) and validation (Yale) cohorts</p>
<p>association of B2M mRNA expression with OS in the non-immunotherapy treated TCGA HNSCC ccohort</p>
<p>LAIR-1 expression in different compartments and its association with survival Validation Cohort 250 (YTMA-250). (A) LAIR-1 protein tumor stroma compartments. (B) stromal both LUAD LUSC-NSCLC subtypes. (C) Association of CD68 the outcome.</p>
<p>Representative figures of staining by different antibody clones. Representative QIF images LAIR-1 clones targeting non-overlapping epitopes in a lung test array (YTMA–295) containing 35 tumor cores stained (A) E7X61 clone, (B) NKT25 (C) 1A10 clone and (D) 1E4 clone. (E) The quantification the four CK: green, LAIR-1: red, DAPI: blue. fluorescent channels where each marker was acquired were shown brackets.</p>
<p>b2m expression range, multivariate analysis of pfs and os association with response disease control in Athens cohort</p>
<p>Antibody Validation. (A) LAIR-1 mean RNA expression across nine tumor types. Representative QIF images of antibody validation using four different anti-LAIR-1 clones (B) E7X61, (C) NKT25, (D) 1A10 and (E) 1E4 targeting non-overlapping epitopes in a lung test array (YTMA–295) containing 35 cores. CK: green, LAIR-1: red, DAPI: blue. Three were tested earlier the experiment hence serial TMA sections E7X61 was few away from TMAs later at stage experiment. The fluorescent channels where...
<p>b2m expression range, multivariate analysis of pfs and os association with response disease control in Yale cohort</p>
<p>signal to noise ratio plots for tumor, leukocyte and macrophage compartments</p>
<p>expression of immune-related and immune-checkpoint markers in B2M high vs low groups</p>
<div><p>Targeting the interaction of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) and its ligands has been shown to reinstate antitumor immunity. In addition, introduction LAIR-1 decoy protein, LAIR-2, sensitizes previously resistant lung tumors programmed death-1 (PD-1) blockade, indicating potential as an alternative marker for anti-PD-1 resistance in cancer. Here, we assessed compared with death-ligand 1 (PD-L1) expression various tumors, a focus on non–small...